Categories: News

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:
Date: Thursday, March 14, 2024
Time: 5:00 p.m. EDT / 2:00 p.m. PDT
Dial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b725cac9cc6
Webcast Registration: http://investors.atyrpharma.com/events-and-webcasts

Participants who wish to join the conference call by telephone must register at the above dial-in registration link in order to receive the dial-in number and a personalized PIN code that will be required to access the call. Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page. For more information or questions, please contact aTyr’s investor relations team at investorrelations@atyrpharma.com.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Contact:  
Ashlee Dunston  
Director, Investor Relations and Public Affairs               
adunston@atyrpharma.com  

Staff

Recent Posts

Decisely Notifies Individuals of Data Security Incident

ALPHARETTA, Ga., June 13, 2025 /PRNewswire/ -- Decisely learned of a data security incident that may…

10 hours ago

Abstractive Health Launches Clinical Time Machine, the First AI Game Built on Real Historical Patient Records

NEW YORK--(BUSINESS WIRE)--#digitalhealth--Abstractive Health has launched Clinical Time Machine, an AI-driven simulation that immerses physicians…

16 hours ago

The Berwyn Group Appoints Adam Wilson as General Manager of Healthcare

Veteran Leader Brings Deep Industry Expertise to Advance Berwyn's Healthcare Strategy INDEPENDENCE, Ohio, June 13,…

16 hours ago

Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®

BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture…

16 hours ago

Skypoint Launches Lia and Scribe: AI-Powered Agents Redefining Clinical Workflow Efficiency and Social Determinants of Health (SDOH) Data Capture

PORTLAND, Ore., June 13, 2025 /PRNewswire/ -- Skypoint, a leading provider of HITRUST r2-certified AI platform…

22 hours ago

Prior to FIFA Club World Cup Kickoff, FC Mother and Omya Launch Landmark Joint Venture to Fund “Life Years” as Part of World Cup of Healing Legacy Project

First-of-its-kind joint venture funds longevity gains and maternal healing through football, creating a new category…

22 hours ago